Ruben Mesa

Ruben Mesa, PhDRuben Mesa PhD
UT Health San Antonio Cancer Center, San Antonio


Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia:  Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial


Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)



Ask Speakers


Medical Information Request